id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-003435-ke0az7nf	Schlake, Thomas	mRNA as novel technology for passive immunotherapy	2018-10-17		.txt	text/plain	15190	850	40	Recombinant technologies further expanded the available therapies based on mAbs. In vitro antibody selection technologies like phage or ribosome display were developed to enable the generation of highly specific human mAbs out of libraries that may even be naïve for the specific antigens [31] [32] [33] [34] [35] [36] 1 Schematic illustration comparing active immunization and passive antibody immunotherapies. While T cell engineering for adoptive transfer inevitably requires the use of nucleic acids encoding a target-specific receptor, antibody immunotherapy can deploy recombinant proteins. However, the effects of mRNA modifications on translation, immunostimulation and resulting protein expression appear to be variable, for instance dependent on the type of target cells. In comparison to a single transfer of cells with retroviral CAR expression, an mRNA-encoded receptor required three consecutive lymphocyte infusions to obtain a comparable antitumor effect [262] .	./cache/cord-003435-ke0az7nf.txt	./txt/cord-003435-ke0az7nf.txt